CLL.L Regulatory News (CLL)

5 November 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Directorate Change

Cello Health plc (AIM: CLL), the global healthcare focused advisory group, is pleased to announce the appointment of Chris Jones as Non-Executive Chairman of the Group with immediate effect, following the retirement of Allan Rich from the Board.

Chris Jones has been a Non-Executive Director of Cello since October 2016. He was formerly Global Chairman and CEO of J Walter Thompson Co based in New York, part of WPP Group plc. Amongst other directorships, Chris is also a director of Becton Dickinson & Co, the major US-based multinational medical technology company.

Mark Scott, Chief Executive, commented: "The Board wishes to wholeheartedly thank Allan Rich for his invaluable contribution to Cello over the years from its inception. Chris knows the group and the healthcare industry well and can help guide the Board through the Group's next stage of growth and development."

Enquiries:

Appendix

As at today's date, Mr Jones holds 22,726 ordinary shares in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule 2(g) of the AIM Rules for Companies in respect of Mr Jones' appointment.